Sandra Levy
ARTICLES BY THIS AUTHOR
- 3/1/2021
Hikma intros generic Northera
Droxidopa capsules had a market value of approximately $353 million in the 12 months ended November 2020, according to IQVIA. - 3/1/2021
Slayback names Paul Campanelli to board
Endo chairman Paul Campanelli is joining the Slayback Pharma board of directors. - 3/1/2021
Report: Merck to help J&J make COVID-19 vaccine
President Biden is expected to announce today that Merck will help J&J make its newly authorized COVID-19 vaccine in an effort to sharply increase the supply of the single-shot vaccine, per a report in the Washington Post. - 3/1/2021
Hy-Vee awards $75K to 55 schools across the Midwest
Hy-Vee's $75,000 pledge to local schools and $12,500 in additional prizes for Hy-Vee customers contributes to its commitment to supporting teachers, students and customers in response to the pandemic. - 3/1/2021
Kinney Drugs hosting COVID-19 vaccine clinics in partnership with Association on Aging
Kinney Drugs is partnering with the Association on Aging in New York to host COVID-19 vaccination clinics in 21 counties over 10 weeks for people 65 years old and older. - 3/1/2021
Lupin obtains FDA OK for generic Northera
Droxidopa capsules had a market value of $352 million, according to IQVIA December 2020 data. - 2/28/2021
Janssen’s COVID-19 vaccine gets emergency use authorization, shipments begin
Johnson & Johnson expects to supply enough of the single-shot vaccine by the end of March for 20 million people, with the goal of 100 million doses in the first half of 2021. - 2/28/2021
Study tracks adherence to MS therapies in pregnant women, impact on hospitalizations
A Walgreens study, in collaboration with AllianceRx Walgreens Prime showed that adherence to disease-modifying therapies in pregnant MS patients can reduce hospitalization events and costs. - 2/28/2021
Oncopeptides obtains FDA nod for Pepaxto
Oncopeptides' Pepaxto is the first anticancer peptide-drug conjugate approved in multiple myeloma. - 2/28/2021
Perrigo to sell generic Rx business for $1.55B
Perrigo is selling its generic prescription business to Altaris Capital Partners for a total consideration of $1.55 billion, including $1.5 billion in cash.
